Evidence map›Paper›PMID 37973951›Full record

ArticleOncogene2024

Targeting DGAT1 inhibits prostate cancer cells growth by inducing autophagy flux blockage via oxidative stress.

Haiying Cui, Yao Wang, Tong Zhou, Limei Qu, Xiaoling Zhang, Yingdi Wang, Mingyue Han, Shuo Yang, Xinhua Ren, Guixia Wang and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. TRMT6/TRMT61A-mediated tRNA mCellular & molecular biology letters · 2026
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Haiying CuiDepartment of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China.
Yao WangDepartment of Orthopedics, The Second Hospital Jilin University, Changchun, 130021, Jilin Province, China.
Tong Zhou *Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China.
Limei Qu *Department of Pathology, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China.
Xiaoling ZhangKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China.ORCID 0000-0002-5012-9107
Yingdi WangDepartment of Urology, Jilin Oncological Hospital, Changchun, 130021, Jilin Province, China.
Mingyue HanDepartment of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China.
Shuo YangDepartment of Clinical Nutrition, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China.
Xinhua RenDepartment of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China.
Guixia WangDepartment of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China. gwang168@jlu.edu.cn.ORCID 0000-0001-8107-616X
Xiaokun GangDepartment of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China. gangxk@jlu.edu.cn.ORCID 0000-0003-0855-6954
Jilin University · CNSecond Affiliated Hospital of Jilin University · CN

Funding

Department of Science and Technology of Jilin Province (Jilin Province Science and Technology Department) 20190901006JCDepartment of Science and Technology of Jilin Province (Jilin Province Science and Technology Department) 20210101355JCDepartment of Science and Technology of Jilin Province (Jilin Province Science and Technology Department) YDZJ202202CXJD042National Natural Science Foundation of China (National Science Foundation of China) 82272993
6 · The paper itself

Abstract

Impaired macroautophagy/autophagy flux has been implicated in the treatment of prostate cancer (PCa). However, the mechanism underlying autophagy dysregulation in PCa remains unknown. In the current study, we investigated the role of diacylglycerol acyltransferases 1 (DGAT1) and its potential effects on cellular energy homeostasis and autophagy flux in PCa. The results of immunohistochemical staining suggested that DGAT1 expression was positively corrected with tumor stage and node metastasis, indicating DGAT1 is an important factor involved in the development and progression of PCa. Furthermore, targeting DGAT1 remarkably inhibited cell proliferation in vitro and suppressed PCa growth in xenograft models by triggering severe oxidative stress and subsequently autophagy flux blockage. Mechanically, DGAT1 promoted PCa progression by maintaining cellular energy homeostasis, preserving mitochondrial function, protecting against reactive oxygen species, and subsequently promoting autophagy flux via regulating lipid droplet formation. Moreover, we found that fenofibrate exhibits as an upstream regulator of DGAT1. Fenofibrate performed its anti-PCa effect involved the aforementioned mechanisms, and partially dependent on the regulation of DGAT1. Collectively. These findings indicate that DGAT1 regulates PCa lipid droplets formation and is essential for PCa progression. Targeting DGAT1 might be a promising method to control the development and progression of PCa. Schematic representation of DGAT1 affects autophagy flux by regulating lipid homeostasis and maintaining mitochondrial function in prostate cancer (PCa). PCa is characterized up-regulation of DGAT1, leading to the translocation of free fatty acids into lipid droplets, thereby preventing PCa cell from lipotoxicity. Inhibition of DGAT1 suppresses growth of PCa by inducing oxidative stress and subsequently autophagy flux blockage. Further, the current results revealed that fenofibrate exhibits as an upstream regulator of DGAT1, and fenofibrate plays an anti-PCa role partially dependent on the regulation of DGAT1, suggesting a potential therapeutic approach to ameliorate this refractory tumor.

Indexed as

FenofibrateProstatic NeoplasmsAutophagyDiacylglycerol O-AcyltransferaseHumansMaleOxidative StressProstateDGAT1 protein, humanDiacylglycerol O-AcyltransferaseFenofibrate

Identifiers

PMID37973951
OpenAlexW4388734500

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.